Three Chinese companies kicked off their bookbuilding for their Hong Kong initial public offerings on Monday, with their scheduled debuts on June 30.
Zhejiang Laifual Drive, a leading Chinese manufacturer of core precision transmission components, plans to raise at most HK$1.15 billion by offering 13.44 million H shares. The offer price is between HK$77 and HK$85.5 per share. The entry fee for each board lot of 100 shares is HK$8,636.2.
Guangdong True Health Medical Technology Development, a developer of medical equipment for lung cancer treatment, plans to offer 3.57 million H shares, raising up to HK$480 million. The offer price is between HK$119.3 and HK$135.4. It has an entry fee of HK$2,735.3 per board lot of 20 shares.
Antitoxins and immune-serum biological producer Jiangxi Institute of Biological Products aims to raise up to HK$470 million by offering 36.24 million H shares. The offer price is between HK$9.33 and HK$13.06 per share. Each board lot of 500 shares has an entry fee of HK$6,595.9.